Protagonist Therapeutics (PTGX) Stock Price, News & Analysis

Company Overview

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) is a clinical-stage biopharmaceutical company focused on developing peptide-based medicines for chronic immune-mediated and hematologic diseases. The company uses its proprietary technology platform to design peptides intended to selectively interact with disease-relevant biological targets.

Protagonist’s pipeline includes icotrokinra, formerly known as JNJ-2113, an investigational oral peptide that selectively targets the interleukin-23 receptor. The program is being developed through a collaboration with Johnson & Johnson for conditions including psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis. The company is also developing rusfertide, formerly known as PTG-300, an investigational hepcidin mimetic designed to regulate iron availability and treat polycythemia vera and other myeloproliferative neoplasms. Rusfertide is being advanced through a collaboration with Takeda.

Founded in 2006, Protagonist is headquartered in Newark, New Jersey, and conducts research and clinical development activities through collaborations and partnerships serving international markets. The company is led by Dinesh V. Patel, who serves as president and chief executive officer.

Key Stats

• Today's Range: $136.02 to $139.11
• 50-Day Range: $136.28 to $158.62
• 52-Week Range: $73.08 to $160.81
• Volume: 707,736 shs
• Average Volume: 870,665 shs
• Market Capitalization: $8.84 billion
• P/E Ratio: 132.31
• Dividend Yield: N/A
• Price Target: $154.44
• Consensus Rating: Buy

Protagonist Therapeutics Stock Analysis - MarketRank™

Protagonist Therapeutics scored higher than 39% of companies evaluated by MarketBeat, and ranked 702nd out of 870 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Protagonist Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 strong buy rating, 16 buy ratings, 1 hold rating, and no sell ratings.

Upside Potential

Protagonist Therapeutics has a consensus price target of $154.44, representing about 13.1% upside from its current price of $136.55.

Amount of Analyst Coverage

Protagonist Therapeutics has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Protagonist Therapeutics are expected to decrease in the coming year, from $4.22 to ($0.07) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Protagonist Therapeutics is 132.31, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 41.07.

Price to Earnings Ratio vs. Sector

The P/E ratio of Protagonist Therapeutics is 132.31, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 201.79.

Price to Book Value per Share Ratio

Protagonist Therapeutics has a P/B Ratio of 13.89. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

15.23% of the float of Protagonist Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Protagonist Therapeutics has a short interest ratio ("days to cover") of 11.49, which indicates bearish sentiment.

Change versus previous month

Short interest in Protagonist Therapeutics has recently increased by 14.81%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Protagonist Therapeutics does not currently pay a dividend.

Dividend Growth

Protagonist Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.26

News Sentiment

Protagonist Therapeutics has a news sentiment score of 0.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 13 news articles for Protagonist Therapeutics this week, compared to 4 articles on an average week.

Search Interest

Only 1 people have searched for PTGX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

7 people have added Protagonist Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 133% compared to the previous 30 days.

Company Ownership

• Score: 1.6 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Protagonist Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $41,443,786.00 in company stock.

Percentage Held by Insiders

5.19% of the stock of Protagonist Therapeutics is held by insiders.

Percentage Held by Institutions

98.63% of the stock of Protagonist Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/05/2026
• Today: 10/15/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:PTGX
• CIK: 1377121
• Web: www.protagonist-inc.com
• Phone: (510) 474-0170
• Fax: N/A
• Employees: 141
• Year Founded: 2006

Price Target and Rating

• Average Price Target for Protagonist Therapeutics: $154.44
• High Price Target: $190.00
• Low Price Target: $82.00
• Potential Upside/Downside: +13.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 18 Analysts

Profitability

• EPS (Trailing Twelve Months): $1.03
• Trailing P/E Ratio: 132.31
• Forward P/E Ratio: 32.36
• P/E Growth: N/A
• Net Income: -$130.15 million
• Net Margins: 29.40%
• Pretax Margin: 29.91%
• Return on Equity: 12.03%
• Return on Assets: 11.23%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 21.71
• Quick Ratio: 21.71

Sales & Book Value

• Annual Sales: $46.02 million
• Price / Sales: 192.01
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $9.83 per share
• Price / Book: 13.89

Miscellaneous

• Outstanding Shares: 64,710,000
• Free Float: 61,350,000
• Market Cap: $8.84 billion
• Optionable: Optionable
• Beta: 1.53